{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T23:53:23Z","timestamp":1779148403887,"version":"3.51.4"},"reference-count":42,"publisher":"Pharmaceutical Society of Japan","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2016]]},"DOI":"10.1248\/bpb.b15-01022","type":"journal-article","created":{"date-parts":[[2016,5,31]],"date-time":"2016-05-31T18:05:29Z","timestamp":1464717929000},"page":"915-919","source":"Crossref","is-referenced-by-count":14,"title":["Recent Progress in Analytical Methods for Determination of Urinary 3-Hydroxypropylmercapturic Acid, a Major Metabolite of Acrolein"],"prefix":"10.1248","volume":"39","author":[{"given":"Kyohei","family":"Higashi","sequence":"first","affiliation":[{"name":"Graduate School of Pharmaceutical Sciences, Chiba University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuei","family":"Igarashi","sequence":"additional","affiliation":[{"name":"Graduate School of Pharmaceutical Sciences, Chiba University"},{"name":"Amine Pharma Research Institute, Innovation Plaza at Chiba University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Toida","sequence":"additional","affiliation":[{"name":"Graduate School of Pharmaceutical Sciences, Chiba University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Stevens JF, Maier CS. Acrolein: Sources, metabolism, and biomolecular interactions relevant to human health and disease. <i>Mol. Nutr. Food Res.<\/i>, <b>52<\/b>, 7\u201325 (2008).","DOI":"10.1002\/mnfr.200700412"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Sharmin S, Sakata K, Kashiwagi K, Ueda S, Iwasaki S, Shirahata A, Igarashi K. Polyamine cytotoxity in the presence of bovine serum amine oxidase. <i>Biochem. Biophys. Res. Commun.<\/i>, <b>282<\/b>, 228\u2013235 (2001).","DOI":"10.1006\/bbrc.2001.4569"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Sakata K, Kashiwagi K, Sharmin S, Ueda S, Igarashi K. Acrolein produced from polyamines as one of the ureamic toxins. <i>Biochem. Soc. Trans.<\/i>, <b>31<\/b>, 371\u2013374 (2003).","DOI":"10.1042\/bst0310371"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Anderson MM, Hazen SL, Hsu FF, Heinecke JW. Human neutrophils employ the myeloperoxidase\u2013hydrogen peroxide\u2013chloride system to convert hydroxyl-amino acids into glycolaldehyde, 2-hydroxypropanal, and acrolein. A mechanism for the generation of highly reactive \u03b1-hydroxy and \u03b1,\u03b2-unsaturated aldehydes by phagocytes at sites of inflammation. <i>J. Clin. Invest.<\/i>, <b>99<\/b>, 424\u2013432 (1997).","DOI":"10.1172\/JCI119176"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Uchida K, Kanematsu M, Morimitsu Y, Osawa T, Noguchi N, Niki E. Acrolein is a product of lipid peroxidation reaction. Formation of free acrolein and its conjugate with lysine residues in oxidized low density lipoproteins. <i>J. Biol. Chem.<\/i>, <b>273<\/b>, 16058\u201316066 (1998).","DOI":"10.1074\/jbc.273.26.16058"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Maeshima T, Honda K, Chikazawa M, Shibata T, Kawai Y, Akagawa M, Uchida K. Quantitative analysis of acrolein-specific adducts generated during lipid peroxidation\u2013modification of proteins <i>in vitro<\/i>: Identification of <i>N<\/i><sup>\u03c4<\/sup>-(3-propanal) histidine as the major adduct. <i>Chem. Res. Toxicol.<\/i>, <b>25<\/b>, 1384\u20131392 (2012).","DOI":"10.1021\/tx3000818"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Uchida K. Current status of acrolein as a lipid peroxidation product. <i>Trends Cardiovasc. Med.<\/i>, <b>9<\/b>, 109\u2013113 (1999).","DOI":"10.1016\/S1050-1738(99)00016-X"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Shao B, O\u2019brien KD, McDonald TO, Fu X, Oram JF, Uchida K, Heinecke JW. Acrolein modifies apolipoprotein A-I in the human artery wall. <i>Ann. N. Y. Acad. Sci.<\/i>, <b>1043<\/b>, 396\u2013403 (2005).","DOI":"10.1196\/annals.1333.046"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Sakata K, Kashiwagi K, Sharmin S, Ueda S, Irie Y, Murotani N, Igarashi K. Increase in putrescine, amine oxidase, and acrolein in plasma of renal failure patients. <i>Biochem. Biophys. Res. Commun.<\/i>, <b>305<\/b>, 143\u2013149 (2003).","DOI":"10.1016\/S0006-291X(03)00716-2"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Tomitori H, Usui T, Saeki N, Ueda S, Kase H, Nishimura K, Kashiwagi K, Igarashi K. Polyamine oxidase and acrolein as novel biochemical markers for diagnosis of cerebral stroke. <i>Stroke<\/i>, <b>36<\/b>, 2609\u20132613 (2005).","DOI":"10.1161\/01.STR.0000190004.36793.2d"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Yoshida M, Tomitori H, Machi Y, Katagiri D, Ueda S, Horiguchi K, Kobayashi E, Saeki N, Nishimura K, Ishii I, Kashiwagi K, Igarashi K. Acrolein, IL-6 and CRP as markers of silent brain infarction. <i>Atherosclerosis<\/i>, <b>203<\/b>, 557\u2013562 (2009).","DOI":"10.1016\/j.atherosclerosis.2008.07.022"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Yoshida M, Higashi K, Kobayashi E, Saeki N, Wakui K, Kusaka T, Takizawa H, Kashiwado K, Suzuki N, Fukuda K, Nakamura T, Watanabe S, Tada K, Machi Y, Mizoi M, Toida T, Kanzaki T, Tomitori H, Kashiwagi K, Igarashi K. Correlation between images of silent brain infarction, carotid atherosclerosis and white matter hyperintensity, and plasma levels of acrolein, IL-6 and CRP. <i>Atherosclerosis<\/i>, <b>211<\/b>, 475\u2013479 (2010).","DOI":"10.1016\/j.atherosclerosis.2010.03.031"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Waragai M, Yoshida M, Mizoi M, Saiki R, Kashiwagi K, Takagi K, Arai H, Tashiro J, Hashimoto M, Iwai N, Uemura K, Igarashi K. Increased protein-conjugated acrolein and amyloid-\u03b240\/42 ratio in plasma of patients with mild cognitive impairment and Alzheimer\u2019s disease. <i>J. Alzheimer\u2019s Dis.<\/i>, <b>32<\/b>, 33\u201341 (2012).","DOI":"10.3233\/JAD-2012-120253"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Mizoi M, Yoshida M, Saiki R, Waragai M, Uemura K, Akatsu H, Kashiwagi K, Igarashi K. Distinction between mild cognitive impairment and Alzheimer\u2019s disease by CSF amyloid \u03b240 and \u03b242, and protein-conjugated acrolein. <i>Clin. Chim. Acta<\/i>, <b>430<\/b>, 150\u2013155 (2014).","DOI":"10.1016\/j.cca.2014.01.007"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Noiri E, Yamada S, Nakao A, Tsuchiya M, Masaki I, Fujino K, Nosaka K, Ozawa T, Fujita T, Uchida K. Serum protein acrolein adducts: utility in detecting oxidant stress in hemodialysis patients and reversal using a vitamin E-bonded hemodialyzer. <i>Free Radic. Biol. Med.<\/i>, <b>33<\/b>, 1651\u20131656 (2002).","DOI":"10.1016\/S0891-5849(02)01138-3"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Zhang X, Lai Y, McCance DR, Uchida K, McDonald DM, Gardiner TA, Stitt AW, Curtis TM. Evaluation of <i>N<\/i><sup>\u025b<\/sup>-(3-formyl-3,4-dehydropiperidino)lysine as a novel biomarker for the severity of diabetic retinopathy. <i>Diabetologia<\/i>, <b>51<\/b>, 1723\u20131730 (2008).","DOI":"10.1007\/s00125-008-1071-3"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Higashi K, Yoshida M, Igarashi A, Ito K, Wada Y, Murakami S, Kobayashi D, Nakano M, Sohda M, Nakajima T, Narita I, Toida T, Kashiwagi K, Igarashi K. Intense correlation between protein-conjugated acrolein and primary Sj\u00f6gren\u2019s syndrome. <i>Clin. Chim. Acta<\/i>, <b>411<\/b>, 359\u2013363 (2010).","DOI":"10.1016\/j.cca.2009.11.032"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Daimon M, Sugiyama K, Kameda W, Saitoh T, Oizumi T, Hirata A, Yamaguchi H, Ohnuma H, Igarashi M, Kato T. Increased urinary levels of pentosidine, pyrraline and acrolein adduct in type 2 diabetes. <i>Endocr. J.<\/i>, <b>50<\/b>, 61\u201367 (2003).","DOI":"10.1507\/endocrj.50.61"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Tsukahara H, Sekine K, Uchiyama M, Kawakami H, Hata I, Todoroki Y, Hiraoka M, Kaji M, Yorifuji T, Momoi T, Yoshihara K, Beppu M, Mayumi M. Formation of advanced glycosylation end products and oxidative stress in young patients with type 1 diabetes. <i>Pediatr. Res.<\/i>, <b>54<\/b>, 419\u2013424 (2003).","DOI":"10.1203\/01.PDR.0000076662.72100.74"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Yoshida M, Mikami T, Higashi K, Saiki R, Mizoi M, Fukuda K, Nakamura T, Ishii I, Nishimura K, Toida T, Tomitori H, Kashiwagi K, Igarashi K. Inverse correlation between stroke and urinary 3-hydroxypropyl mercapturic acid, an acrolein\u2013glutathione metabolite. <i>Clin. Chim. Acta<\/i>, <b>413<\/b>, 753\u2013759 (2012).","DOI":"10.1016\/j.cca.2012.01.020"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Yoshida M, Higashi K, Kuni K, Mizoi M, Saiki R, Nakamura M, Waragai M, Uemura K, Toida T, Kashiwagi K, Igarashi K. Distinguishing mild cognitive impairment from Alzheimer\u2019s disease with acrolein metabolites and creatinine in urine. <i>Clin. Chim. Acta<\/i>, <b>441<\/b>, 115\u2013121 (2015).","DOI":"10.1016\/j.cca.2014.12.023"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) DeJarnett N, Conklin DJ, Riggs DW, Myers JA, O\u2019Toole TE, Hamzeh I, Wagner S, Chugh A, Ramos KS, Srivastava S, Higdon D, Tollerud DJ, DeFilippis A, Becher C, Wyatt B, McCracken J, Abplanalp W, Rai SN, Ciszewski T, Xie Z, Yeager R, Prabhu SD, Bhatnagar A. Acrolein exposure is associated with increased cardiovascular disease risk. <i>J. Am. Heart Assoc.<\/i>, <b>3<\/b>, e000934 (2014).","DOI":"10.1161\/JAHA.114.000934"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Uchida K, Kanematsu M, Sakai K, Matsuda T, Hattori N, Mizuno Y, Suzuki D, Miyata T, Noguchi N, Niki E, Osawa T. Protein-bound acrolein: potential markers for oxidative stress. <i>Proc. Natl. Acad. Sci. U.S.A.<\/i>, <b>95<\/b>, 4882\u20134887 (1998).","DOI":"10.1073\/pnas.95.9.4882"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Furuhata A, Ishii T, Kumazawa S, Yamada T, Nakayama T, Uchida K. <i>N<\/i><sup>\u025b<\/sup>-(3-Methylpyridinium)lysine, a major antigenic adduct generated in acrolein-modified protein. <i>J. Biol. Chem.<\/i>, <b>278<\/b>, 48658\u201348665 (2003).","DOI":"10.1074\/jbc.M309401200"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Kaye CM. Biosynthesis of mercapturic acids from allyl alcohol, allyl esters and acrolein. <i>Biochem. J.<\/i>, <b>134<\/b>, 1093\u20131101 (1973).","DOI":"10.1042\/bj1341093"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Giles PM. The biosynthesis of 3-hydroxypropylmercapturic acid from cyclophosphamide. <i>Xenobiotica<\/i>, <b>9<\/b>, 745\u2013762 (1979).","DOI":"10.3109\/00498257909042343"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Parent RA, Caravello HE, Sharp DE. Metabolism and distribution of [2,3-<sup>14<\/sup>C]acrolein in Sprague-Dawley rats. <i>J. Appl. Toxicol.<\/i>, <b>16<\/b>, 449\u2013457 (1996).","DOI":"10.1002\/(SICI)1099-1263(199609)16:5<449::AID-JAT369>3.0.CO;2-9"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Parent RA, Paust DE, Schrimpf MK, Talaat RE, Doane RA, Caravello HE, Lee SJ, Sharp DE. Metabolism and distribution of [2,3-<sup>14<\/sup>C]acrolein in Sprague-Dawley rats. II. Identification of urinary and fecal metabolites. <i>Toxicol. Sci.<\/i>, <b>43<\/b>, 110\u2013120 (1998).","DOI":"10.1006\/toxs.1998.2462"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Mascher DG, Mascher HJ, Scherer G, Schmid ER. High-performance liquid chromatographic-tandem mass spectrometric determination of 3-hydroxypropylmercapturic acid in human urine. <i>J. Chromatogr. B: Biomed. Sci. Appl.<\/i>, <b>750<\/b>, 163\u2013169 (2001).","DOI":"10.1016\/S0378-4347(00)00385-6"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Carmella SG, Chen M, Zhang Y, Zhang S, Hatsukami DK, Hecht SS. Quantitation of acrolein-derived (3-hydroxypropyl)mercapturic acid in human urine by liquid chromatography-atmospheric pressure chemical ionization tandem mass spectrometry: effects of cigarette smoking. <i>Chem. Res. Toxicol.<\/i>, <b>20<\/b>, 986\u2013990 (2007).","DOI":"10.1021\/tx700075y"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Schettgen T, Musiol A, Kraus T. Simultaneous determination of mercapturic acids derived from ethylene oxide (HEMA), propylene oxide (2-HPMA), acrolein (3-HPMA), acrylamide (AAMA) and <i>N<\/i>,<i>N<\/i>-dimethylformamide (AMCC) in human urine using liquid chromatography\/tandem mass spectrometry. <i>Rapid Commun. Mass Spectrom.<\/i>, <b>22<\/b>, 2629\u20132638 (2008).","DOI":"10.1002\/rcm.3659"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Yan W, Byrd GD, Brown BG, Borgerding MF. Development and validation of a direct LC-MS-MS method to determine the acrolein metabolite 3-HPMA in urine. <i>J. Chromatogr. Sci.<\/i>, <b>48<\/b>, 194\u2013199 (2010).","DOI":"10.1093\/chromsci\/48.3.194"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Zhang X, Xiong W, Shi L, Hou H, Hu Q. Simultaneous determination of five mercapturic acid derived from volatile organic compounds in human urine by LC-MS\/MS and its application to relationship study. <i>J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci.<\/i>, <b>967<\/b>, 102\u2013109 (2014).","DOI":"10.1016\/j.jchromb.2014.07.013"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Watzek N, Scherbl D, Feld J, Berger F, Doroshyenko O, Fuhr U, Tomalik-Scharte D, Baum M, Eisenbrand G, Richling E. Profiling of mercapturic acids of acrolein and acrylamide in human urine after consumption of potato crisps. <i>Mol. Nutr. Food Res.<\/i>, <b>56<\/b>, 1825\u20131837 (2012).","DOI":"10.1002\/mnfr.201200323"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Winegard HM, Toennies G, Block RJ. Detection of sulfur-containing amino acids on paper chromatograms. <i>Science<\/i>, <b>108<\/b>, 506\u2013507 (1948).","DOI":"10.1126\/science.108.2810.506"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Eckert E, Drexler H, G\u00f6en T. Determination of six hydroxyalkyl mercapturic acids in human urine using hydrophilic interaction liquid chromatography with tandem mass spectrometry (HILIC-ESI-MS\/MS). <i>J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.<\/i>, <b>878<\/b>, 2506\u20132514 (2010).","DOI":"10.1016\/j.jchromb.2009.09.003"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Maestri L, Ghittori S, Imbriani M. Determination of urinary mercapturic acids of styrene in man by high-performance liquid chromatography with fluorescence detection. <i>J. Chromatogr. B: Biomed. Appl.<\/i>, <b>687<\/b>, 387\u2013394 (1996).","DOI":"10.1016\/S0378-4347(96)00250-2"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Conklin DJ, Haberzettl P, Lesgards JF, Prough RA, Srivastava S, Bhatnagar A. Increased sensitivity of glutathione <i>S<\/i>-transferase P-null mice to cyclophosphamide-induced urinary bladder toxicity. <i>J. Pharmacol. Exp. Ther.<\/i>, <b>331<\/b>, 456\u2013469 (2009).","DOI":"10.1124\/jpet.109.156513"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Sanduja R, Ansari GA, Boor PJ. 3-Hydroxypropylmercapturic acid: a biologic marker of exposure to allylic and related compounds. <i>J. Appl. Toxicol.<\/i>, <b>9<\/b>, 235\u2013238 (1989).","DOI":"10.1002\/jat.2550090406"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Khan M, Sekhon B, Jatana M, Giri S, Gilg AG, Sekhon C, Singh I, Singh AK. Administration of <i>N<\/i>-acetylcysteine after focal cerebral ischemia protects brain and reduces inflammation in a rat model of experimental stroke. <i>J. Neurosci. Res.<\/i>, <b>76<\/b>, 519\u2013527 (2004).","DOI":"10.1002\/jnr.20087"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Yoshida M, Tomitori H, Machi Y, Hagihara M, Higashi K, Goda H, Ohya T, Niitsu M, Kashiwagi K, Igarashi K. Acrolein toxicity: Comparison with reactive oxygen species. <i>Biochem. Biophys. Res. Commun.<\/i>, <b>378<\/b>, 313\u2013318 (2009).","DOI":"10.1016\/j.bbrc.2008.11.054"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Tomitori H, Nakamura M, Sakamoto A, Terui Y, Yoshida M, Igarashi K, Kashiwagi K. Augmented glutathione synthesis decreases acrolein toxicity. <i>Biochem. Biophys. Res. Commun.<\/i>, <b>418<\/b>, 110\u2013115 (2012).","DOI":"10.1016\/j.bbrc.2011.12.143"}],"container-title":["Biological &amp; Pharmaceutical Bulletin","Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/39\/6\/39_b15-01022\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,8]],"date-time":"2019-09-08T22:48:49Z","timestamp":1567982929000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/39\/6\/39_b15-01022\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b15-01022","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}